Research Triangle Park, NC - Feb. 12, 1997 - Quintiles Transnational Corp. (Nasdaq: QTRN) has announced the opening of an office in Hong Kong, further strengthening its position as the leading contract pharmaceutical and healthcare company in the developing East Asia region.

"Economic development in the Far East is creating demand for more sophisticated healthcare services," said Dennis Gillings, Ph.D., Chairman and Chief Executive Officer of Quintiles Transnational Corp. "We're also seeing growing demand from the healthcare industry for access to patient populations in East Asia. The opening of this office is evidence of our strong commitment to healthcare in that region of the world."

The Hong Kong office is headed by K.C. Lau, Ph.D., who previously worked at Hong Kong University and Roche Pharmaceuticals, where he acquired extensive experience in Good Clinical Practices and clinical trials in China and Hong Kong. The Hong Kong office already is monitoring clinical studies in China, Taiwan and Hong Kong involving diseases such as chronic hepatitis B, live cancer, and hypercholesterolemia, among others. The office also has a strategic alliance with an academic oncology department that operates a phase I oncology unit.

Quintiles first established a presence in the Pacific Rim in 1993, when it opened offices in Australia and Japan. In June 1995 the company established Quintiles East Asia Pte Ltd. in Singapore to provide training and clinical trials capabilities in that region.

Quintiles Transnational Corp. is a leading provider of full-service contract research, sales and marketing services to the worldwide pharmaceutical, biotechnology and medical device industries. The company also provides healthcare policy consulting and disease and health information management services to the healthcare industry. Headquartered near Research Triangle Park, North Carolina, Quintiles has more than 60 operating units in 20 countries and more than 7,300 employees worldwide.